Related Experiment Video
Updated: May 12, 2026
05:52
Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model
Published on: November 4, 2021
The next generation HydroCoil: initial clinical experience with the HydroFill embolic coil
John W D Speirs1, Thomas H Burke, Stefanie Y Lee
1Department of Radiology, Division of Interventional Radiology, Hotel-Dieu Grace Hospital, Windsor, Ontario, Canada.
Journal of Neurointerventional Surgery
|April 25, 2013
Summary
The new HydroFill coil safely treats intracranial aneurysms, showing high long-term occlusion rates. This embolization system offers a promising option for aneurysm treatment and recurrence prevention.
Area of Science:
- Neurosurgery
- Interventional Neuroradiology
- Vascular Neurology
Background:
- Complete packing of intracranial aneurysms reduces recurrence.
- The HydroCoil Embolization System (HES) enhances volumetric filling for sustained occlusion.
- The HydroFill coil is a next-generation device designed for improved HES deployment.
Purpose of the Study:
- To evaluate the initial clinical safety and effectiveness of the HydroFill coil.
- To assess immediate and long-term outcomes of HydroFill coil embolization.
- To report single-institution experience with a novel embolic coil.
Main Methods:
- Retrospective analysis of 11 patients with 14 aneurysms treated with HydroFill coils.
- Non-randomized, single-arm registry study.
- Angiographic and clinical follow-up for up to 30 months.
Main Results:
- 100% immediate occlusion rate per Raymond scale.
- Mean packing density of 64%.
- 86% complete occlusion at long-term follow-up (13-30 months); 14% required retreatment or showed neck remnants.
Conclusions:
- HydroFill coil deployment is safe in ruptured and unruptured aneurysms.
- The device demonstrates a high rate of long-term aneurysm occlusion without major complications.
- This initial series suggests favorable outcomes for the HydroFill coil in endovascular treatment.
Related Concept Videos
01:19Pulmonary Embolism I: Introduction
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
01:29Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:21Aneurysm II: Clinical Manifestations and Diagnostic Studies
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...